Trials / Recruiting
RecruitingNCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).
Conditions
- T-cell Lymphomas
- NK-Cell Lymphomas
- T-cell Prolymphocytic Leukemia
- T-cell Large Granular Lymphocyte Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib 20mg BID |
| DRUG | Duvelisib | Duvelisib 25mg, 50mg, or 75mg BID |
Timeline
- Start date
- 2021-08-12
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2021-08-18
- Last updated
- 2026-04-09
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05010005. Inclusion in this directory is not an endorsement.